Christoph Rader, PhD, National Cancer Institute/NIH

Christoph Rader, PhD
Christoph Rader, PhD

The Rader laboratory pursues both antibody target and drug discovery strategies toward more specific and more potent treatment options for cancer patients. Their target discovery efforts are aimed at identifying new cell surface antigens suitable for monoclonal antibody (mAb) therapy of cancer. Their drug discovery efforts have the objective to develop and utilize antibody display, antibody engineering, and antibody conjugation methods for improving the potency of mAbs. A particular focus in the Rader lab is devoted to antibody technologies at the interface of biology and chemistry, including the generation of molecularly defined antibody-drug conjugates and chemically programmed mAbs and bispecific antibodies. Collectively, these efforts have unveiled several new candidate targets, created a panel of new mAbs, and led to a diverse assortment of new and refined antibody technologies with broad utility for cancer therapy.

*Now affiliated with The Scripps Research Institute.

Products

References

  1. Hofer T, Tangkeangsirisin W, Kennedy MG, Mage RG, Raiker SJ, Venkatesh K, Lee H, Giger RJ, Rader C. Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector. J Immunol Methods. 2007 Jan 10;318(1-2):75-87.
  2. Kwong KY, Baskar S, Zhang H, Mackall CL, Rader C. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol. 2008 Dec 31;384(5):1143-56.
  3. Rader C. Generation and selection of rabbit antibody libraries by phage display. Methods Mol Biol. 2009;525:101-28, xiv.
  4. Kwong KY, Rader C. E. coli expression and purification of Fab antibody fragments. Curr Protoc Protein Sci. 2009 Feb;Chapter 6:Unit 6.10.
  5. Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, Bishop MR, Rader C. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood. 2009 Nov 12;114(20):4494-502.
  6. Stahl SJ, Watts NR, Rader C, DiMattia MA, Mage RG, Palmer I, Kaufman JD, Grimes JM, Stuart DI, Steven AC, Wingfield PT. Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev. J Mol Biol. 2010 Apr 2;397(3):697-708.
  7. Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One. 2011;6(6):e21018.
  8. Rader C. Generation of human Fab libraries for phage display. Methods Mol Biol. 2012;901:53-79.
  9. Rader C. Selection of human Fab libraries by phage display. Methods Mol Biol. 2012;901:81-99.
  10. Grönwall C, Charles ED, Dustin LB, Rader C, Silverman GJ. Selection of apoptotic cell specific human antibodies from adult bone marrow. PLoS One. 2014 Apr 23;9(4):e95999.